ASSESS: Early Breast Cancer Treatment Decision Support Tool
ASSESS is a free online tool for physicians and their patients that helps make informed decisions about treatment choices for early breast cancer by showing how different options may impact survival.
ASSESS is a free online tool for physicians and their patients that helps make informed decisions about treatment choices for early breast cancer by showing how different options may impact survival.
A shared decision-making tool to make confident, informed treatment decisions
What is ASSESS?
ASSESS is an online tool that helps support early breast cancer treatment decisions by showing how different options may impact survival, similar to the former Adjuvant! Online tool.
Who is ASSESS for?
ASSESS is a tool meant to assist physicians and patients in selecting therapies for recently diagnosed stage I–III breast cancer. ASSESS is best used in consultation with a medical professional and can be used before or during appointments to help guide discussions about the use of some treatments, such as chemotherapy or hormone therapy.
Who developed ASSESS?
ASSESS was developed through a collaboration between Susan G. Komen, the MD Anderson Cancer Center and Yale Cancer Center and was built through an iterative process with input from patients, patient advocates, physicians and researchers.
How does it work?
ASSESS uses data from the U.S. population-based SEER database and from randomized clinical trials to provide personalized 5-year survival estimates based on an individual’s personal and pathologic information. Health information will not be stored; it will only be used to calculate the survival estimate.
What is ASSESS?
ASSESS is an online tool that helps support early breast cancer treatment decisions by showing how different options may impact survival, similar to the former Adjuvant! Online tool.
Who is ASSESS for?
ASSESS is a tool meant to assist physicians and patients in selecting therapies for recently diagnosed stage I–III breast cancer. ASSESS is best used in consultation with a medical professional and can be used before or during appointments to help guide discussions about the use of some treatments, such as chemotherapy or hormone therapy.
Who developed ASSESS?
ASSESS was developed through a collaboration between Susan G. Komen, the MD Anderson Cancer Center and Yale Cancer Center and was built through an iterative process with input from patients, patient advocates, physicians and researchers.
How does it work?
ASSESS uses data from the U.S. population-based SEER database and from randomized clinical trials to provide personalized 5-year survival estimates based on an individual’s personal and pathologic information. Health information will not be stored; it will only be used to calculate the survival estimate.
How to use ASSESS
To get the most accurate results, you’ll need information on:
- Age at diagnosis
- Menopausal status
- BRCA inherited gene mutation status
- Tumor size and grade (I–III)*
- Hormone receptor status (ER/PR)*
- HER2 status*
- Number of positive lymph nodes (i.e., lymph nodes with cancer)*
*This information can usually be found in the pathology report.
To get the most accurate results, you’ll need information on:
- Age at diagnosis
- Menopausal status
- BRCA inherited gene mutation status
- Tumor size and grade (I–III)*
- Hormone receptor status (ER/PR)*
- HER2 status*
- Number of positive lymph nodes (i.e., lymph nodes with cancer)*
*This information can usually be found in the pathology report.
Patient education resources to support informed treatment decision-making
Explore trusted Komen resources to help make treatment decisions and prepare for the next steps:
Support for navigating treatment:
Check back here for updates, research publications and press releases about the ASSESS tool.
